Investing

0 320
CombiMatrix Corp CBMX Stock News

CombiMatrix Corp (NASDAQ: CBMX)

CombiMatrix is having a great time in pre-market trading at the moment, and for good reason. Yesterday, after the closing bell, the company released its earnings report. Below, we’ll talk about what we saw from the earnings report, what we’re seeing from the stock as a result, and what binary options traders should be watching for ahead.





What We Saw From The CBMX Report

As mentioned above, CombiMatrix reported its earnings after the closing bell yesterday, beating expectations. Here’s what we saw from the report…

  • Earnings Per Share – In terms of earnings per share, CBMX did overwhelmingly well. In fact, during the quarter, analysts expected that the company would generate a loss of $0.39 per share. However, the company actually reported a loss of $0.22 per share, blowing away expectations.
  • Revenue – When it comes to revenue, investors received more good news. During the quarter, analysts expected that the company would generate revenue in the amount of $2.68 million. However, the company actually reported revenue for the quarter in the amount of $3.54 million.




How The Stock Reacted To The News

As is always the case, earnings move the market. In this case, this is no different. The strong earnings are leading to strong gains on the stock. Currently (9:20), CBMX is trading at $4.85 per share after a gain of $0.80 per share or 19.75% thus far today.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CBMX. In particular, we’re interested in the company’s progress with regard to its impressive pipeline. Nonetheless, we’ll be watching the stock closely and bringing all news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Aytu BioScience Inc AYTU Stock News

Aytu BioScience Inc (OTCMKTS: AYTU)

Let’s get an important disclosure out of the way quickly: I am long Aytu BioScience, and for good reason.

Now, while some may argue that this statement is merely an overzealous pitch, it isn’t. In fact, the case for AYTU being a hidden gem is just as powerful as it was in December of 2016, when I first presented my thesis. Even though the company’s share price hasn’t been able to catch its footing at the start of this new year, I contend that the fundamentals are already in place to justify a correction to the upside for the stock.

Remember AYTU?

AYTU has not been flying completely under the radar. The stock has enjoyed quite a bit of positive investor sentiment, acknowledging the company’s recent acquisitions as well as Aytu BioScience’s therapeutic and diagnostic platform in urology. Unfortunately, as is the case for many emerging biotech companies, share price is often less reflective of company accomplishment and potential than it is of simple market momentum, either positive or negative.

With the stock trading at roughly a dollar a share, perhaps much of that value is being hamstrung based on the fact that many investors have a misunderstanding of the company’s current position. To that end, perhaps a re-introduction to the company is in order, providing an even more robust thesis as to why AYTU may be undervalued at current levels.

Aytu BioScience Commercial Stage

Since 2016, the general description of AYTU remains the same. The company is a small, commercial stage specialty pharmaceutical company that remains focused on bringing innovative treatments and diagnostics to urologists around the world. Unlike many emerging companies that have no commercialization to speak of, AYTU currently has three FDA approved drugs and one CE Marked diagnostic device that hold the potential to address large needs within the urology field, and each of the products come with unique offerings. All four of the company’s products are currently commercialized, and Aytu BioScience has spent the better part of the last year building its fully integrated commercial infrastructure to support sales efforts and to generate revenue-building momentum.

AYTU has four commercially active products in market: Natesto, , ProstaScint, and Primsol each holding regulatory approval in the U.S., and MiOXSYS having regulatory clearance abroad. While Natesto may offer the most compelling reason for investment consideration into AYTU, MiOXSYS, ProstaScint and Primsol deserve a brief overview as well.

MiOXSYS For Male Infertility

MiOXSYS is a first-in-class in-vitro diagnostic device. Already CE marked and its regulatory pathway for U.S approval defined, MiOXSYS is being positioned as a new test that can rapidly help clinicians accurately identify infertile male patients, facilitating appropriate treatment strategies that can be immediately implemented. The speed of the results allows clinicians to take immediate action, improving the patient’s chance of fertility. The MiOXSYS device offers a recurring revenue model from the sale of disposable sensors, similar to a razor/razor blade sales and replacement model.

The market opportunity is substantial, with an international market estimated to be $825 million per year. In the U.S. AYTU’s target market of men between the ages of 25-44 adds additional market potential of nearly $100 million per year. The MiOXSYS device is already establishing a strong global footprint, with the device currently placed in 17 countries worldwide. Sales and revenue guidance is expected to be updated in the coming quarters.

ProstaScint For Cancer Imaging

ProstaScint is an established, proprietary monoclonal antibody imaging agent. It is the only FDA-approved prostate-specific SPECT imaging agent available on the market. ProstaScint works by binding glycoprotein expressed by prostate epithelium, prostate specific membrane antigen (PMSA).

Aytu BioScience’s ProstaScint enables accurate staging and guides appropriate treatment, with emphasis on both high risk and newly diagnosed patients, intended to identify specific organ defined disease. ProstaScint is being further positioned to address treatment failures with post-curative intent to identify candidates for potential localized therapy.

During its clinical trial, ProstaScint’s performance was clinically and statistically relevant. Plus, ProstaScint has already been significantly improved since FDA approval. The imaging produces greater than 95% accuracy, sensitivity, and positive predictive value in intermediate-risk and high-risk patients, demonstrating clear advantages over imaging procedures routinely being used and cleared by the FDA.

ProstaScint is a viable shot on goal, with ProstaScint’s score card indicating a 95.7% success rate for accuracy, a 95.7% success rate for imaging sensitivity, and a 100% success rate in its positive predictive value.

Primsol Solution

Primsol is the second revenue-generating product in the AYTU arsenal. Primsol has an established prescriber base, and the company is currently marketing Primsol in a pediatric co-promotion. AYTU sees opportunity for Primsol to be re-positioned to urologists to treat urinary tract infections.

The product has an opportunity to treat over 8.3 million office visits annually, and is ideal for elderly patients who have difficulty swallowing pills or are allergic to “sulfa” compounds. Like the other products in the Aytu BioScience portfolio, Primsol has advantages over the competition. It is the only FDA-approved liquid formulation of trimethoprim, and is the only approved standard of care antibiotic for treating uncomplicated urinary tract infections in a novel formulation without sulfamethoxazole.

Primsol is currently enjoying approximately 26% of current prescriptions being written to treat urinary tract infections, and this is without any aggressive commercial promotions in place.

Now, even though any of the former three products may serve an investor well once AYTU generates the marketing muscle to provide aggressive sales support, the largest near-term opportunity may lay in Natesto, another FDA approved product.

Natesto May Captain The Growth

Acknowledging the promise and market position of MiOXSYS, ProstaScint, and Primsol, Natesto offers perhaps the most lucrative current opportunity for AYTU, and Natesto has the potential to both disrupt the urology market and significantly improve the standard of care for patients. Natesto is the only FDA-approved nasally administered testosterone, and is prescribed and indicated to treat hypogonadism, commonly known as low-testosterone.

The prospective market for a potentially better treatment like Natesto is significant, with the market being pegged at roughly $2 billion per year for testosterone replacement therapies. The goal at Aytu BioScience is for management and the sales team to demonstrate why Natesto is a better option to treat low testosterone compared the current standard care of treatment. When making the comparison between Natesto and other treatments, a few aspects clearly stand out right from the get-go.

First, Natesto is nasally administered. In fact, it’s the only testosterone replacement therapy in the world that is delivered in that manner, and this benefit alone may allow the therapy to gain traction and aggressively grab a large portion of the $2 billion market. Natesto has been gaining traction since its launch in late 2016, with revenues continuing to ramp higher as the company sales force penetrates the barriers to entry, which sometimes keep more advantageous therapies, like Natesto, at a disadvantage when trying to face down the marketing and sales budgets of large pharmaceutical companies. While these barriers take time to dismantle, ultimately the patients have the right to be treated with the most effective course of treatment, and also to be offered product alternatives that have a highly proven profile of producing less side effects and unintended results.

For instance, Natesto, by being nasally administered, eliminates almost all of the exposure risk associated to testosterone treatment products that are applied topically to the skin or through painful subcutaneous or intramuscular injections. This advantage alone is significant, and represents a huge advance over currently marketed products.

What’s The Big Deal About Aytu’s Natesto?

“Huge opportunity”, he yelled – and here’s why:

Current methods of treatment require a patient with low testosterone to topically apply the treatment product on their skin, whereby it carries a substantial risk of skin transference from the patient to any person who has even minimal skin contact with the patient. Even in the event of casual contact with a female partner or child, there is concern that there can be a transference of testosterone to a family member or friend, which could potentially trigger a host of unwanted male-trait-enhancing effects in women and children. For patients who would rather not see their wives or daughters growing full beards as a side effect of testosterone contact, both the convenience and safety factor of Natesto is reason enough to choose the nasally administered treatment. From there, as long as the medication is properly secured, the likelihood of unintended testosterone treatments to people not requiring the therapy is almost entirely eliminated.

The FDA has not been blind to the issue, either. The potential transference of testosterone to unintended recipients has caused them to assign a “black box warning” to all topically applied testosterone treatment therapies. In contrast, Natesto does not have the same warning, alleviating a major safety concern while also dramatically improving the way testosterone is delivered. The question then becomes, why aren’t all doctors prescribing Natesto? Other than contending that big pharma has the power to control and influence doctor’s prescribing habits, the rest of the answer is “it makes no sense as to why Natesto is not the current standard of care.”

The “it makes no sense as to why Natesto is not the current standard of care” answer is based on several apparent product improvements and patient compliance efficiencies. First, AYTU’s Natesto is administered only 2-3 times daily, with one pump into each nostril. Patients achieve maximum concentration within 40 minutes after the first administration. These results are dramatically quicker than current methods, and because of the relatively short duration of action, patients are also afforded the flexibility in achieving their optimal testosterone levels throughout the day. Additionally, this 2-3 times daily administration more closely resembles the natural daily rhythm of hormonal production in the male body – ultimately enabling men with Low T to feel more like themselves.

From an IP standpoint, Natesto is patented into the year 2024, with multiple strong patent families protecting the product. Further, AYTU will enjoy an exclusive right to license Natesto in the U.S for at least that long, providing enough runway to address the benefits of Natesto to both urologists and to an industry, educating them on the treatment benefits of AYTU’s therapy and potentially changing the method as to how practitioners are treating low testosterone patients. And, while the trends take time, AYTU is demonstrating prescription growth for Natesto, and company management has expressed that, in 2016, current prescription levels had already exceeded expectations.

Other Natesto Benefits

Focused on an exclusive licensing agreement in the U.S., AYTU is targeting the 13 million men already diagnosed with low testosterone. Currently, the options include topical treatments, all which come with a “black box warning”. The warning is significant, by the way – it indicates that unintended transference could cause androgen/male trait enhancing side effects in women, including hair growth, male pattern baldness and additional male trait changes. These same effects may occur in children as well.

These risks are not only casual touch related, as transference can also occur from unwashed clothes, unwashed areas in a shower or bath, and unwashed counter space where the product had been stationed. For those who are feeling frisky, the warning says to be sure to wash the application area thoroughly with soap and water prior to contact. This may cause opportune moments to become quite inopportune, and relying on a set of wet-naps may not offer the protection intended.

In the pivotal clinical trial studying the safety and efficacy of Natesto, 91% of patients in the three time daily dosing study group achieved normal testosterone levels at day 90. Additionally, greater than 70% of men in the twice daily treatment group achieved normal testosterone levels at day 90 as well.

Of significant importance to many male patients, Natesto demonstrated notable improvement in the International Index of Erectile Function, causing statistically significant improvements in each of the five domains of erectile function, with a supporting P value of P<0.0001. The majority of the effect on erectile dysfunction was evident by day 30 of the study.

Natesto Position And Opportunity

Natesto is being positioned for active men with low-testosterone between the ages of 45-64, for whom convenience, discretion, and quick use of a testosterone replacement treatment is important. The nasal application is brief and easy to use, and does not interfere with or complicate travel or work schedules. Unlike topical solutions, it’s not time consuming to administer and allows for discreet dosing. It also eliminates other options, including inconvenient and costly in-office procedures with regular implants that have been shown to cause side effects, such as the ones shown on the Testopel prescribing information.

With 70% of the men in the Natesto pivotal trial indicating that they would switch from their current replacement therapy to treatment with Natesto, AYTU is encouraged to seize upon the market potential staring them in the face. With even a 5% market share, AYTU can be in a position to generate over $100 million in annual sales, and with prescriptions reaching an all-time high coming out of 2016, AYTU is positioned to capitalize further as the marketing and sales promotion continue to gain traction in the market.

To prove their commitment, AYTU, on Wednesday, announced that the company has increased its sales team by 20%, primarily driven by the increasing growth of Natesto, in both prescription and revenue. This move further punctuates the fact that Natesto is continuing to gain traction and successfully penetrate the low testosterone and testosterone replacement market. This addition establishes the AYTU footprint in over 40 territories, inclusive of multiple territories in large metropolitan areas that are being divided to optimize coverage. With the additional and coordinated geographic coverage, AYTU is targeting the estimated 7000 U.S. testosterone replacement therapy and low testosterone prescribers. AYTU expects that the sales force expansion will be completed by the end of June 2017.

AYTU Upside Opportunity

After reading the prospects for AYTU, the picture of the emerging gem scenario may have become more clear for investors. AYTU already has four commercialized, approved products in place, and is gaining momentum quarter over quarter.

Natesto was launched in August of 2016 and has seen consistent growth every month since that time, being supported by a full commercial infrastructure at AYTU. Beyond Natesto, AYTU is continuing to show sales growth of ProstaScint and Primsol, with ambitions to reclaim historical prescribing rates and to grow ProstaScint through distribution and out-licensing deals outside of the U.S.

For MiOXSYS, AYTU plans to leverage the substantial, growing market opportunity with support from the world’s leading centers in male infertility, with expectations to complete U.S. clinical and regulatory developments, leading to a U.S. product launch in 2017.

Management is strong, and features an experienced and entrepreneurial based management team with proven success in launching and growing specialty pharmaceutical companies. The founding management team, inclusive of Josh and Jarrett Disbrow, grew Arbor Pharmaceuticals from inception to over $127 million in net revenues in less than five years.

The company has over 50 employees, 35 of which are dedicated sales people. After recently completing a cash raise, and with warrants expected to generate additional near term capital, AYTU will be positioned to capitalize on immediate opportunities available to the company. With three FDA-approved products, and a platform that is addressing significant market opportunities, the modest $11 million market cap at the time of this writing appears to be measurably understated.

When all is said and done, gems don’t attract their ultimate value until they are cut and polished. The same standard can be applied to AYTU. The company has four promising products, with Natesto leading the way to drive near term growth and generous revenue opportunities for the company. Once the Natesto machine is in gear, investors can expect those revenues to offer the financial means necessary to generate traction for the other products in the AYTU platform.

To quote the great and prolific entertainer, Rihanna…once the pieces of the entire AYTU platform fall into motion, AYTU may surely “shine bright like a diamond.”

Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.

While I seek to uncover emerging companies that I feel have true value and potential, it’s important that investors assign an appropriate time horizon to each of their investments, understanding that emerging companies need time to mature.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.

Additional Disclosure: I am long AYTU.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 2074
Pernix Therapeutics Holdings Inc PTX Stock News

Pernix Therapeutics Holdings Inc (NASDAQ: PTX)

Finally, PTX shareholders have come into some positive news, a welcome filing that can help erase the long time frowns that have been etched onto the faces of longtime PTX holders, myself included.

Not only do the markets work in mysterious ways, the court system does as well. Still reeling from PTX”s most recent legal setback regrading its marketing rights for drugs just over a week ago, the U.S. District Court in Delaware provided a ray of sunshine, and the effects can have a far reaching and lasting effect for PTX shareholders.





Pernix Gets A Break And Value

For smarties like me, there was never any doubt that the ‘096 and ‘742 patents were being infringed. It was just plain obvious, and why it took hundreds of thousands of dollars to litigate beats the little bit of sense out of me. I was only a phone call away and could have settled this case months ago for a #4 Double Quarter Pounder meal at McD’s.

Seriously, Pernix, as the licensee, had the goods in the bag, clearly distinguishing its proprietary value in Zohydro ER, proving it was distinct in both technology and abuse deterrent compound, as well as in mechanism. The patents in question involved the abuse deterrent compounds and it mechanism to inhibit potential abuse. Both the ‘742 and ‘096 patents are well written, with original claims dating back to 1998 for ‘742 and 2015 for ‘096. The patents are protected until 2019 and 2034, receptively. The active ingredient is hydrocodone bitartrate, part of a widely abused family of pain killing drugs. The real case, though, was about the the technology and abuse deterrent compounds that surround that hydrocodone, making that good stuff hard to get to if the patient does not follow proper dosing instructions..




As with all court decisions, the decision is lengthy and somewhat confusing at times, and while the court makes reference to parts of the whole not necessarily being infringed, the sum of the parts, stated by the court read as , “having considered the entire case, the substantial evidence in the record, the parties post-trial submissions, and the applicable law, the court concludes that Activis’ proposed products infringe the asserted claims of the ‘096, but do not infringe the asserted claims of the ‘742 patents”. HOWEVER, because no ruling can be quite so simple, parts of the ‘742 stand, causing the court to publish the following remedy, “…..Under 35 U.S.C. 271(e)(4)(A), the effective date of any FDA approval of Activis’ ANDA No. 20-6952 shall be a date not earlier than the later expiration date of the ‘096 and ‘742 patents, including any extensions and marketing exclusivities (September 2034)

(Civil Action No. 14-1118-GMS)

Court Decision

In a nutshell, Actavis, its officers, agents, employees, et al, shall be enjoined from engaging in the commercial manufacture, use, offer to sell, or sale with the United States, or importation into the United States of Activis’ ANDA product prior to the expiration of the ‘096 and ‘742 patents.

So, as PTX shareholders, perhaps we may rejoice for a day or two, and even enjoy a possible new trend higher, one that drives the price high enough to attract hungry pharmaceutical investors to bid the stock to a potential buyout at double digit levels, instead of the “Lincoln” that many of us fear.

But, one step at a time. While this is a great victory, and a much needed breath of fresh air, PTX still has some work to do. It’s time for management to harness the value within this decision, and make the company real pretty, with shiny bells and whistles. From there, maybe they can consider packaging the company for sale to an interested party that is willing to pay fair value for PTX. Fair value for most is the price they paid, assuming an investment was made prior to six months ago. I’ll take the highest fair value available, by the way.

As long as the respirator is removed, shareholders stand a solid chance of PTX regaining its footing and marching forward into greener pastures. The drugs under management are strong, and with this issue no longer hanging over their head, shareholders hold hope that better times are ahead.

Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.

While I seek to uncover emerging companies that I feel have true value and potential, it’s important that investors assign an appropriate time horizon to each of their investments, understanding that emerging companies need time to mature.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.

Additional Disclosure: I have no position in any stock mentioned, but may initiate a long position in PTX within the next 72 hours.

Update Feb 23, 11:14 EST – PTX is having a great day following yesterday’s news. While the stock is seeing some ups and some downs, strong gains seem to be here to stay. At the moment, the stock is trading at $3.92 per share after a gain of $1.18 per share or 43.06% thus far today.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 640
Cree, Inc. CREE Stock News

Cree, Inc. (NASDAQ: CREE)

Cree is having an incredibly interesting day in the market today. At the opening bell, the stock was trading in the red. As soon as trading started, the stock quickly pushed to the green before falling back to the red and remained relatively flat throughout the morning. However, minutes ago, that all changed as the stock started to run for the top. Below, we’ll talk about what we’re seeing from CREE, why, and what we’ll be watching for ahead.





What We’re Seeing From CREE

As mentioned above, CREE is having an interesting day in the market, to say the least. At the open of the market, the stock was trading in the red before spiking to the green. That didn’t last, however, as the stock spiked back down right to where it was. Throughout the morning, we saw some movement, but the stock remained red. That is, until minutes ago when it started to spike toward the top. At the moment (11:28), CREE is trading at $27.36 per share after a gain of $0.22 per share (0.79%) thus far today.

Why The Stock Is Spiking Upward

As is usually the case, our friends at Trade Ideas were the first to inform us of the gains on CREE. As soon as we received the alert, the CNA Finance team started digging to see if we could dig up the cause of the gains. It didn’t take long to dig up. While there has been no fundamental news released by the company that would lead to such gains, there is a rumor surfacing.




At the moment, all over social media, we’re seeing a rumor surrounding Cree. That rumor is that there is a private equity group that is interested in acquiring a large part of – or all of – the company. The rumor doesn’t offer any details with regard to who the private equity group is, how much of the company they wish to buy, nor the price per share at which they are going to make an offer.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on CREE. In particular, we’re watching to see if there is any validity to the rumor. Considering that there has been no confirmation from Cree and the rumor is very vague, chances are that it’s not going to happen. However, we could be wrong. We’ll continue to follow the story and bring it to you as it breaks!

Update (12:46): CREE just made another spike upward and is continuing to make a run. The stock is currently trading at $27.71 per share after a gain of $0.57 per share (2.11%) thus far today. The most recent spike seems to be correlated with a mention of the stock by CNBC’s Pete Najarian. We’ll continue to follow the story and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










DryShips Inc. DRYS Stock News

DryShips Inc. (NASDAQ: DRYS)

DryShips is having a very bad day in the market today, only falling further after yesterday’s declines. While the stock was trading in the green at the open, that didn’t last very long. As soon as the trading session started, the stock started to dive, quickly making it to the red and beyond. Below, we’ll talk about what we’re seeing from DRYS, why, and what we’ll be watching for ahead.





What We’re Seeing From DRYS

As mentioned above, DryShips isn’t having the best of days in the market today. In fact, the stock is seeing some big losses. In the pre-market, things looked like they might go well. In fact, the stock opened the day slightly in the green, thanks to strong pre-market activity. Nonetheless, at the open, it took a dive, and it has been falling ever since. At the moment (11:08), DRYS is trading at $2.75 per share after a loss of $0.53 per share (16.16%) thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas brought the alert to us first about the downward movement on DRYS. As soon as we received the alert, the CNA Finance team started working to see why the stock was falling so hard. The truth is that there has been no fundamental news released that would suggest such strong declines. Nonetheless, we believe we know the reason for the fall.




A short while ago, DryShips announced a $200 million fund raise. While most experts covering the story saw it as incredibly dillutive and not likely to be in the best interest of investors, excitement surrounding the raise sent the stock higher. However, that excitement has died off, and now investors are back to concerns.

At the end of the day, DRYS isn’t in the best position at the moment. Not only is the company likely to hit some major financial headwinds soon, there are also allegations of potential fraud on behalf of the CEO that have been surfacing for weeks. With no new positive news, investors are forced to move based on what they know about the company; unfortunately, that’s not good news for the stock price.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on DRYS. In particular, we’re watching for an update from the company in an attempt to stop the bleeding. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Update (11:43): DRYS continues on the steady downtrend. Currently, the stock is trading at $2.68 per share after a loss of $0.60 per share (18.45%) thus far today. Considering the rate of the fall, it wouldn’t be unrealistic for the stock to close down between 20% and 25% today. Further declines are likely to come as the bears take charge and the bulls abandon ship!

UPDATE Feb 23, 11:07 – Things don’t seem to be getting any better as DRYS continues the plunge. At the moment, the stock is trading at $2.26 per share after a loss of $0.44 per share or 16.30% thus far today. Considering the momentum, chances are that there is still room to fall!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 419
Alimera Sciences Inc ALIM Stock News

Alimera Sciences Inc (NASDAQ: ALIM)

Alimera Sciences is having an incredibly strong day in the market today. At the opening bell, the stock was trading well into the green before dipping downward back to the break even point in the first few minutes. However, since then, we’ve seen continuous upward movement, driving the stock to impressive gains. Below, we’ll talk about what we’re seeing from ALIM, why, and what we’ll be watching for ahead.





What We’re Seeing From ALIM

As mentioned above, Alimera Sciences is having a great day in today’s trading session. When the session opened for the day, the stock was already trading in the green. Shortly after the open, the stock corrected, falling to the break even point before hitting support and deciding to rocket upward. At the moment (10:47), ALIM is trading at $1.36 per share after a gain of $0.11 per share or 8.48% thus far today.

Why The Stock Is Soaring

As is usually the case, our friends at Trade Ideas were the first to notify us of the upward movement on ALIM. As soon as we got the notification, the CNA Finance team started digging to see exactly why the stock was soaring. It didn’t take long to uncover the story. The gains are the result of news surrounding the FDA.




Early this morning, a press release by the company announced that Health Canada has accepted the company’s New Drug Submission. The submission surrounds ILUVIEN(R) and has been accepted for review. The treatment is designed to treat macular edema in patients who have previously been treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. If approved, the treatment could be overwhelmingly profitable for Alimera Sciences, ultimately, causing exciting among investors.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ALIM. In particular, we’ll be watching the news surrounding the New Drug Submission and of course, hoping for the best. After all, if it is approved, this treatment could lead to tremendous profits for the company and shareholders alike. Nonetheless, we’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Internap Corp INAP Stock News

Internap Corp (NASDAQ: INAP)

Internap is having an incredibly strong day in the market today. As soon as the trading session opened, the stock was already trading dramatically in the green. While we did see a bit of a correction shortly after the bell, it didn’t last long, and now, the stock is headed back upward. Below, we’ll talk about what we’re seeing from INAP, why, and what we’ll be watching for ahead.





What We’re Seeing From INAP

As mentioned above, Internap is having an overwhelmingly strong day in the market today. At the opening bell, the stock was already trading on impressive gains. While it did correct a bit since then, the stock found support well ahead of the break even point and is currently headed back upward. At the moment (10:08), INAP is trading at $2.69 per share after a gain of $0.88 per share or 48.61% thus far today.

Why The Stock Is Gaining

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on INAP. As soon as we received the notification, the CNA Finance team went to work to see if we could uncover the cause of the movement. In this case, it didn’t take very long. The gains are the result of a fund raising effort that went well.




Internap announced a private placement of about 23.8 million shares early this morning. The shares of common stock sold for a price of $1.81 each, grossing approximately $43 million. The buyers of these shares were a group of investors that includes affiliates of or funds managed by GAMCO Investors as well as accounts advised by Avenir Corporation. In a statement, Peter D. Aquino, President and CEO at INAP had the following to offer…

The confidence demonstrated by our investors in the future of INAP is extremely motivating to the entire management team as we continue our comprehensive operations improvement initiative… The speed with which our new team is moving to right-size our business and invest in sales and marketing to capture strong market demand for Colocation and Cloud Services is impressive. The next steps in the 2017 transformation of the new INAP is to approach the market as two pure plays, complete our debt refinancing, and begin to consider strategic opportunities to bolster organic growth.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on INAP. In particular, we’ll be watching as the company continues on the restructuring process, toward what we believe will be a far more efficient and profitable endpoint. Nonetheless, we’ll keep a close eye on the progress and continue to bring the updates to you as they break!

Update (11:51): INAP is on a slow, yet steady downward path. At the moment it is trading at $2.28 per share. While that is quite a bit lower than it was at the time of this article’s publication, the gains are still impressive, currently at 25.97, and the stock is still likely to close well in the green.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Under Armour Inc Class A UAA Stock News

Under Armour Inc Class A (NYSE: UAA)

Under Armour was off to what seemed like it could have been a rough day in the market today. After starting the day off well into the green, the stock quickly took a dive, making it to the red within the first hour. While it seemed as though all hope was lost for the day, the stock started to spike toward the top minutes ago, quickly making it to the green. Below, we’ll talk about what we’re seeing from UAA, why, and what we’ll be watching for ahead.





What We’re Seeing From UAA

As mentioned above, Under Armour wasn’t having the best of days in the market today. While the stock started the day off in the green, it quickly made a run for the red, making it to the red within the first half hour. However, minutes ago, the stock went from red to green in what seemed like no time at all. Currently (10:14), UAA is trading at $22.07 per share after a gain of $0.29 per share (1.33%) thus far today.

Why The Stock Is Spiking

As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains on UAA. As soon as we received the alert, the CNA Finance team started working to see why the stock was making a run for the top. It didn’t take long to find the reason for the gains. Ultimately, the spike is being caused by a rumor.




At the moment, if you search for Under Armour on your favorite social network, chances are that you will find the rumor too. At the moment, there’s chatter surfacing that the company may be acquired. Now, keep in mind that the rumor is incredibly vague. No one is suggesting who the buyer might be nor at what price.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on UAA. In particular, we’re watching to see if there is any validity to the acquisition rumors happening at the moment. After all, if a takeover does happen, it could return tremendous value to shareholders. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Cemtrex Inc CETX Stock News

Cemtrex Inc (NASDAQ: CETX)

Cemtrex looked like it was going to have a relatively normal day in the market early on. When the opening bell rang, the stock was trading in the green, and throughout about the first 15 minutes, it stayed above the breakeven point. However, minutes ago, the stock started to take a dive. Below, we’ll talk about what we’re seeing from CETX, why, and what we’ll be watching for ahead.





What We’re Seeing From CETX

As mentioned above, Cemtrex seemed to be having a relatively normal start to the trading session today. At the opening bell, the stock was already trading slightly in the green. From there, we saw some upward and some downward movement, but nothing was worth writing home about. That is, until minutes ago when the stock started to spiral downward. Currently (9:53), CETX is trading at $4.71 per share after a loss of $0.41 per share (8.01%) thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas were the first to inform us of the losses on CETX. As soon as we received the alert, the CNA Finance team started digging to see exactly why the stock was falling. It didn’t take long to uncover the story. At the moment, it seems as though investors are spooked, as allegations have been waged against the company.




We found the allegations via social media, and regardless of which social network is your favorite, you should be able to find them too. All you’ll need to do is search for either “Cemtrex” or “CETX” and the posts should pop up. Unfortunately, any allegations of fraud tend to send stocks sliding out of control, as the allegation is generally the first step toward an investigation and a potentially massive headache for the company.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CETX. In particular, we’ll be digging deeper into the fraud allegations to see if there is any validity to them. We’ll also be watching the story as it unfolds and working to bring you any new developments as they break!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 339
Cellectar Biosciences Inc CLRB Stock News

Cellectar Biosciences Inc (NASDAQ: CLRB)

While it is early on in the market at the moment, that’s not stopping Cellectar Biosciences from seeing gains. At the open of the trading session, the stock was already trading well in the green. The gains are the result of an announcement surrounding a key Phase 1 clinical trial. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for ahead with regard to CLRB.





What We’re Seeing From CLRB

As mentioned above, Cellectar Biosciences is having a relatively strong start to the trading session today. At the open, the stock was already trading well into the green. While we did see some downward movement shortly after the bell, the stock has reached support and is currently headed back upward. At the moment (9:43), CLRB is trading at $2.63 per share after a gain of $0.04 per share or 1.54% thus far today.

Why The Stock Is Headed Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the upward movement on CLRB. As soon as the CNA Finance team received the alert, we started digging to see exactly what was causing the upward movement. In this particular case, it didn’t take long to dig up the story. The gains are the result of an announcement surrounding a Phase 1 clinical trial.




Early this morning in pre-market hours, Cellectar Biosciences announced that after successfully completing Cohort 3, the company has no initiated its fourth cohort of its Phase 1 clinical trial of CLR 131. In this cohort, patients will receive 31.25 mCi/m2 of CLR 131 as a single dose infusion. This is a 25% increase from cohort 3. The goal of the Phase 1 study is to establish a maximum tolerated single dose of CLR 131. In a statement, Jim Caruso, president and CEO of CLRB, had the following to offer…

Our enthusiasm for CLR 131’s potential in multiple myeloma patients continues to grow given the positive safety, efficacy markers, progression-free survival and median overall survival results that we have observed to date in the Phase 1 trial, particularly given such a heavy pretreated patient population… We will explore the potential enhanced clinical benefits of a two-dose regimen in our imminent Phase II study, and look forward to updating investors on results of the fourth cohort when available.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CLRB. In particular, we’ll be paying close attention to continued progression with regard to CLR-131 and we are excited for the coming results of Phase I, Cohort 4. Nonetheless, we’ll be watching the news closely and we will continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Thought Leader Discussions

AzurRx BioPharma Inc. AZRX Stock News

0 814
AzurRx BioPharma Inc. (NASDAQ: AZRX) Since first covering AzurRx in December of 2016, many investors have asked me to further expand on the technology and...